technology

PharmEasy halves loss to Rs 2,533 crore in FY24, revenue dips 15%


PharmEasy has reported a 14.7% decline in its revenue for 2023-24 to Rs 5,664 crore from Rs 6,644 crore in FY23 while its net loss fell to Rs 2,533 crore from Rs 5,212 crore, the Mumbai-based online pharmacy.

A reduction in goodwill impairment charges to Rs 582 crore last year from Rs 2,826 crore in FY23 helped Mumbai-based API Holdings, which operates PharmEasy, cut its net loss sharply.

Sales of medicines (goods) for FY24 were Rs 5,008 crore, while revenue from lab tests and other services stood at Rs 652 crore.

PharmEasy published these numbers on its website.

Total expenses for the year were Rs 7,255 crore, reflecting a reduction from Rs 8,974 crore in the previous year, but remaining significant in comparison to revenue. Employee expenses decreased to Rs 699 crore from Rs 1,283 crore, indicating the cost optimisation undertaken by the firm.


Inventory levels were reduced to Rs 555 crore from Rs 688 crore, but trade receivables stood at Rs 706 crore, highlighting challenges in collections.

Discover the stories of your interest


This comes after a significant cap table recapitalisation at the online pharmacy at a 90% discount to its peak valuation of $5.6 billion in 2021. Manipal Group Chief Ranjan Pai and other investors pumped in Rs 3,500 crore through a rights issue to service its debt and restructure the business. Prosus Ventures, TPG, Temasek, Abu Dhabi’s ADQ, and Amansa Capital are among other investors who participated in the rights issue in November 2023.Since the restructuring, PharmEasy has been focusing on reducing its cash burn to become profitable while growing at a sustainable rate.

Readers Also Like:  EU's Vestager meets French tech firm Mistral AI amid competition concerns

This has led to rivals like Tata-owned 1mg and Apollo 24X7 gaining market share. The overall rate of discounting has also come down across industry players, including Flipkart and Amazon India.

In FY24, the company’s exceptional costs included Rs 342 crore in early redemption charges for non-convertible debentures. Depreciation and amortization expenses amounted to Rs 216 crore, compared to Rs 243 crore in the prior year.

Besides Siddharth Shah, CEO of PharmEasy, Dhaval Shah, Dharmil Sheth, Harsh Parekh, and Hardik Dedhia are the other co-founders of the company.

This comes after a significant cap table recapitalisation at the online pharmacy at a 90% discount to its peak valuation of $5.6 billion in 2021. Manipal Group Chief Ranjan Pai and other investors pumped in Rs 3,500 crore through a rights issue to service its debt and restructure the business. Prosus Ventures, TPG, Temasek, Abu Dhabi’s ADQ, and Amansa Capital are among other investors who participated in the rights issue in November 2023.

Besides Siddharth Shah, the current CEO of PharmEasy, Dhaval Shah, Dharmil Sheth, Harsh Parekh, and Hardik Dedhia are the other co-founders of the company.



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.